Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide

Expert Review of Hematology

Volumn 8, Issue 6, 2015, Pages 765-783

  Salihoglu, Ayse ^a   Ar, Muhlis Cem ^a   Soysal, Teoman ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

B cell malignancy; B cell receptor signaling pathway inhibitor; duvelisib; fostamatinib; ibrutinib; idelalisib; immunomodulatory drugs; lenalidomide; non Hodgkin's lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; B LYMPHOCYTE RECEPTOR; B LYMPHOCYTE RECEPTOR SIGNALING INHIBITOR; BENDAMUSTINE; BORTEZOMIB; CHLORAMBUCIL; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPHOSPHAMIDE; DASATINIB; DEXAMETHASONE; DOXORUBICIN; DUVELISIB; ENTOSPLETINIB; FLUDARABINE; FOSTAMATINIB; IBRUTINIB; IDELALISIB; IMMUNOMODULATING AGENT; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; MYELOID DIFFERENTIATION FACTOR 88; OBINUTUZUMAB; OFATUMUMAB; PREDNISOLONE; PROTEIN BCL 2; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE; VON WILLEBRAND FACTOR; ANGIOGENESIS INHIBITOR; THALIDOMIDE;

ANTICOAGULANT THERAPY; ANTIPROLIFERATIVE ACTIVITY; ARTHRALGIA; ATRIAL FIBRILLATION; B LYMPHOCYTE; B LYMPHOCYTE LYMPHOPROLIFERATIVE DISEASE; BONE MARROW SUPPRESSION; BURNING SENSATION; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLITIS; COUGHING; CREATININE CLEARANCE; CYTOPENIA; DIARRHEA; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF; IMMUNOSURVEILLANCE; INDOLENT LYMPHOMA; INFUSION RELATED REACTION; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; LYMPHOCYTOSIS; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NAUSEA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY NEUROPATHY; SIGNAL TRANSDUCTION; SINUSITIS; STOMATITIS; SUBDURAL HEMATOMA; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; TUMOR FLARE; TUMOR LYSIS SYNDROME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; IMMUNOLOGY; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; PATHOLOGY;

ANGIOGENESIS INHIBITORS; B-LYMPHOCYTES; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; SIGNAL TRANSDUCTION; THALIDOMIDE;

EID: 84947613335     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2015.1091301     Document Type: Review

References (131)

1. Macias-Perez IM, Flinn IW. B-cell receptor pathobiology and targeting in NHL. Curr Oncol Rep 2012;14(5):411-18
2. Portis T, Longnecker R. Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway. Oncogene 2004;23(53):8619-28
3. Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011;117(23):6287-96
4. Lee CS, Rattu MA, Kim SS. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib. J Oncol Pharm Pract 2014. [Epub ahead of print]
5. Young RM, Shaffer AL 3rd, Phelan JD, Staudt LM. B-cell receptor signaling in diffuse large B-cell lymphoma. Semin Hematol 2015;52(2):77-85
6. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369(1):32-42
7. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369(6):507-16
8. Cheson BD, Byrd JC, Rai KR, et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 2012;30(23):2820-2
9. Sanford DS, Wierda WG, Burger JA, et al. Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab into Clinical Practice. Clin Lymphoma Myeloma Leuk 2015;15(7):385-91
10. Janssen MD. Imbruvica (ibrutinib) package insert. Janssen MD; US: 2013. Available from: www.janssenmd.com/pdf/imbruvica/ PI-Imbruvica.pdf
11. Parmar S, Patel K, Pinilla-Ibarz J. Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia. P T 2014; 39(7):483-519
12. Shah N, Hutchinson C, Rule S. Ibrutinib for the treatment of mantle cell lymphoma. Expert Rev Hematol 2014;7(5):521-31
13. McMullen JR, Boey EJ, Ooi JY, et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood 2014; 124(25):3829-30
14. Levade M, David E, Garcia C, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood 2014;124(26):3991-5
15. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31(1): 88-94
16. Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 2015; 126(6):739-45
17. Wang ML, Hagemeister F, Westin JR, et al. Ibrutinib and Rituximab Are an Efficacious and Safe Combination in Relapsed Mantle Cell Lymphoma: Preliminary Results from a Phase II Clinical Trial. Blood ASH Annual Meeting Abstracts 2014;124(21):627
18. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014;371(3):213-23
19. Chanan-Khan AAA, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study. J Clin Oncol ASCO Annual Meeting Abstracts 2015(33):abstr LBA7005
20. O'Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 2014;15(1):48-58
21. A multi-center study of ibrutinib in combination with obinutuzumab versus chlorambucil in combination with obinutuzumab in patients with treatment naïve CLL or SLL. Available from: https:// clinicaltrials.gov/ct2/show/NCT02264574
22. Farooqui MZ, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol 2015;16(2): 169-76
23. Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 2014;15(10): 1090-9
24. Ibrutinib Versus Ibrutinib + Rituximab (i vs iR) in patients with relapsed chronic lymphocytic Leukemia (CLL). Available from: https://clinicaltrials.gov/ct2/show/ NCT02007044
25. Jaglowski SM, Jones JA, Flynn JM, et al. A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. J Clin Oncol ASCO Annual Meeting Abstracts 2012;30:abstr 6508
26. Jaglowski SM, Jones JA, Flynn JM, et al. A phase 1b/2 study evaluating activity and tolerability of the BTK inhibitor ibrutinib in combination with ofatumumab in patients with chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL) and related diseases. J Clin Oncol ASCO Annual Meeting Abstracts 2014(32):abstr 7009
27. Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 2015;125(16):2497-506
28. Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstrom's macroglobulinemia. N Engl J Med 2015;372(15):1430-40
29. Chakraborty R, Kapoor P, Ansell SM, Gertz MA. Ibrutinib for the treatment of Waldenstrom macroglobulinemia. Expert Rev Hematol 2015;1:11
30. Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 2015;21(8):922-6
31. Younes A, Thieblemont C, Morschhauser F, et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol 2014;15(9):1019-26
32. Yang Y, Shaffer AL 3rd, Emre NC, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012;21(6):723-37
33. Christian B, Kuruvilla J, Smith S, et al. A Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma. Blood ASH Annual Meeting Abstracts 2014;124(21):4476
34. Herman SE, Johnson AJ. Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia. Clin Cancer Res 2012;18(15): 4013-18
35. Hewett YG, Uprety D, Shah BK. Idelalisiba PI3Kdelta targeting agent for B-cell malignancies. J Oncol Pharm Pract 2015
36. Kahl BS, Spurgeon SE, Furman RR, et al. A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood 2014; 123(22):3398-405
37. Iyengar S, Clear A, Bodor C, et al. P110alpha-mediated constitutive PI3K signaling limits the efficacy of p110delta-selective inhibition in mantle cell lymphoma, particularly with multiple relapse. Blood 2013;121(12):2274-84
38. Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014;123(22):3390-7
39. Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001;98(5):1326-31
40. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370(11):997-1007
41. Barrientos JC, Furman RR, Leonard J, et al. Update on a phase I study of the selective PI3Kd inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL. J Clin Oncol, ASCO Annual Meeting Abstracts 2013(31):abstr 7017
42. O'Brien S, Lamanna N, Kipps TJ, et al. Update on a Phase 2 Study of Idelalisib in Combination with Rituximab in Treatment-Naïve Patients 65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Blood ASH Annual Meeting Abstracts 2014;124(21):1994
43. Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 2014; 123(22):3406-13
44. Gopal AK, Kahl BS, de Vos S, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370(11):1008-18
45. Smith MS, Pitcher B, Jung SH, et al. Unexpected and Serious Toxicity Observed with Combined Idelalisib, Lenalidomide and Rituximab in Relapsed/Refractory B Cell Lymphomas: Alliance A051201 and A051202. Blood ASH Annual Meeting Abstracts 2014;124(21):3091
46. Cheah CY, Nastoupil LJ, Neelapu SS, et al. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/ refractory indolent lymphoma. Blood 2015; 125(21):3357-9
47. O'Brien S, Patel M, Kahl BS, et al. Duvelisib (IPI-145), a PI3K-d,g Inhibitor, Is Clinically Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood, ASH Annual Meeting Abstracts 2014;124(21):3334
48. Porcu P, Flinn I, Kahl BS, et al. Clinical Activity of Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-d,g Inhibitor, in Patients Previously Treated with Ibrutinib. Blood ASH Annual Meeting Abstracts 2014;124(21):3335
49. Flinn I, Oki Y, Patel M, et al. a Phase 1 Evaluation of Duvelisib (IPI-145), a PI3K-d,g Inhibitor, in Patients with Relapsed/Refractory iNHL. Blood ASH Annual Meeting Abstracts 2014;124(21):802
50. Flinn I, Patel MR, Maris MB, et al. An Open-Label, Phase Ib Study of Duvelisib (IPI-145) in Combination with Bendamustine, Rituximab or Bendamustine/ Rituximab in Select Subjects with Lymphoma or Chronic Lymphocytic Leukemia. Blood ASH Annual Meeting Abstracts 2014;124(21):4422
51. McAdoo SP, Tam FW. Fostamatinib Disodium. Drugs Future 2011;36(4):273
52. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115(13): 2578-85
53. Currie KS, Kropf JE, Lee T, et al. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase. J Med Chem 2014;57(9):3856-73
54. Sharman J, Hawkins M, Kolibaba K, et al. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood 2015;125(15):2336-43
55. Amrein PC, Attar EC, Takvorian T, et al. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2011;17(9):2977-86
56. Kater AP, Spiering M, Liu RD, et al. Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study. Leuk Res 2014;38(1):34-41
57. Zeldis JB, Knight R, Hussein M, et al. A review of the history, properties, and use of the immunomodulatory compound lenalidomide. Ann N Y Acad Sci 2011;1222:76-82
58. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357(21): 2133-42
59. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357(21):2123-32
60. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352(6):549-57
61. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355(14):1456-65
62. Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008;26(9): 1544-52
63. Witzig TE, Nowakowski GS, Habermann TM, et al. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Ann Oncol 2015; 26(8):1667-77
64. Figaro MK, Clayton W Jr, Usoh C, et al. Thyroid abnormalities in patients treated with lenalidomide for hematological malignancies: results of a retrospective case review. Am J Hematol 2011;86(6):467-70
65. Nowakowski GS, LaPlant B, Macon WR, et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. J Clin Oncol 2015;33(3):251-7
66. Thieblemont C, Delfau-Larue MH, Coiffier B. Lenalidomide in diffuse large B-cell lymphoma. Adv Hematol 2012;2012:861060
67. Eve HE, Rule SA. Lenalidomide-induced tumour flare reaction in mantle cell lymphoma. Br J Haematol 2010;151(4): 410-12
68. Moutouh-de Parseval LA, Weiss L, DeLap RJ, et al. Tumor lysis syndrome/ tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. J Clin Oncol 2007;25(31):5047
69. Wu L, Adams M, Carter T, et al. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008; 14(14):4650-7
70. Witzig TE, Nowakowski GS, Habermann TM, et al. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Ann Oncol 2015
71. Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008;26(30): 4952-7
72. Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009;145(3):344-9
73. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011;22(7):1622-7
74. Eve HE, Carey S, Richardson SJ, et al. Single-agent lenalidomide in relapsed/ refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br J Haematol 2012;159(2):154-63
75. Zinzani PL, Vose JM, Czuczman MS, et al. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol 2013;24(11):2892-7
76. Vose JM, Habermann TM, Czuczman MS, et al. Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation. Br J Haematol 2013;162(5):639-47
77. Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol 2013;31(29):3688-95
78. Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/ 2 clinical trial. Lancet Oncol 2012;13(7): 716-23
79. Ahmadi T, Chong EA, Gordon A, et al. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas. Cancer 2014;120(2):222-8
80. Chong EA, Ahmadi T, Aqui NA, et al. Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas. Clin Cancer Res 2015; 21(8):1835-42
81. Flinn IW, Mainwaring M, Peacock N, et al. Rituximab, Lenalidomide, and Bortezomib in the First-Line or Second-Line Treatment of Patients with Mantle Cell Lymphoma a Phase I/II Trial. Blood, ASH Annual Meeting Abstracts 2012;120:abstr 2748
82. Ruan J, Martin P, Shah BD, et al. Sustained Remission with the Combination Biologic Doublet of Lenalidomide Plus Rituximab As Initial Treatment for Mantle Cell Lymphoma: A Multi-Center Phase II Study Report. Blood ASH Annual Meeting Abstracts 2014;124(21):625
83. Jerkeman M, Albertsson-Lindblad A, Kolstad A, et al. Lenalidomide, Bendamustine, and Rituximab As First-Line Therapy For Patients >65 Years With Mantle Cell Lymphoma: Preliminary Results From The Nordic Lymphoma Group MCL4 (LENA-BERIT) Phase I-II Trial. Blood, ASH Annual Meeting Abstracts 2013;abstr 4377
84. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006;24(34):5343-9
85. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111(11):5291-7
86. Sher T, Miller KC, Lawrence D, et al. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma 2010;51(1): 85-8
87. Badoux XC, Keating MJ, Wen S, et al. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2013; 31(5):584-91
88. Strati P, Keating MJ, Wierda WG, et al. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood 2013;122(5):734-7
89. Chen CI, Paul H, Wang T, et al. Long-term follow-up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia. Br J Haematol 2014;165(5): 731-3
90. James DF, Werner L, Brown JR, et al. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. J Clin Oncol 2014;32(19):2067-73
91. Mato AR, Foon KA, Feldman T, et al. Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCRLite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia. Am J Hematol 2015;90(6): 487-92
92. Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol 2009;27(32):5404-9
93. Leonard J, Jung S-H, Johnson JL, et al. CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. J Clin Oncol ASCO Annual Meeting Abstracts 2012(30):abstr 8000
94. Tuscano JM, Dutia M, Chee K, et al. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. Br J Haematol 2014;165(3):375-81
95. Fowler NH, Davis RE, Rawal S, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 2014;15(12):1311-18
96. Martin P, Jung S-H, Johnson JL, et al. CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma. J Clin Oncol ASCO Annual Meeting Abstracts 2014(32):abstr 8521
97. Tilly H, Morschhauser F, Salles G, et al. Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma. Leukemia 2013;27(1):252-5
98. Tilly H, Morschhauser F, Casasnovas O, et al. Lenalidomide In Combination With R-CHOP (R2-CHOP) In Patients With High Burden Follicular Lymphoma: Phase 2 Study. Blood ASH Annual Meeting Abstracts 2013;abstr 248
99. Combined rituximab and lenalidomide treatment for untreated patients with follicular lymphoma (RELEVANCE). Available from: https://clinicaltrials.gov/ct2/ show/NCT01476787
100. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011;117(22): 5058-66
101. Zinzani PL, Rigacci L, Cox MC, et al. Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice. Leuk Lymphoma 2015; 56(6):1671-6
102. Zinzani PL, Pellegrini C, Derenzini E, et al. Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients. Hematol Oncol 2013; 31(4):223-4
103. Zinzani PL, Pellegrini C, Gandolfi L, et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk 2011;11(6):462-6
104. Wang M, Fowler N, Wagner-Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 2013; 27(9):1902-9
105. Cai Q, Chen Y, Zou D, et al. Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/ refractory aggressive B-cell non-hodgkin lymphoma. Oncotarget 2014;5(17):7368-80
106. Feldman T, Mato AR, Chow KF, et al. Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma. Br J Haematol 2014;166(1):77-83
107. Martín A, Redondo AM, Lopez-Guillermo A, et al. Lenalidomide in combination with R-ESHAP (LR-ESHAP) in patients with relapsed or refractory diffuse large b-cell lymphoma candidates to autologous stem-cell transplantation: a phase 1b study from spanish group geltamo. Blood ASH Annual Meeting Abstracts 2013;abstr 4391
108. Vitolo U, Chiappella A, Franceschetti S, et al. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol 2014;15(7): 730-7
109. Chiappella A, Tucci A, Castellino A, et al. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. Haematologica 2013;98(11):1732-8
110. Nowakowski GS, LaPlant B, Habermann TM, et al. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia 2011;25(12):1877-81
111. Rituximab and combination chemotherapy with or without lenalidomide in treating patients with newly diagnosed stage II-IV Diffuse Large B cell lymphoma. Available from: https://clinicaltrials.gov/ct2/show/ NCT01856192
112. Eckhart W, Hutchinson MA, Hunter T. An activity phosphorylating tyrosine in polyoma T antigen immunoprecipitates. Cell 1979; 18(4):925-33
113. Tucker DL, Rule SA. A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. Ther Clin Risk Manag 2015;11:979-990
114. O'Brien SM. Treatment of chronic lymphocytic leukaemia, where are we heading? Hematol Oncol 2015;33(Suppl 1): 46-9
115. Pan B, Lentzsch S. The application and biology of immunomodulatory drugs (IMiDs) in cancer. Pharmacol Ther 2012; 136(1):56-68
116. Forconi F. Three years of ibrutinib in CLL. Blood 2015;125(16):2455-6
117. Tam CS, O'Brien S, Plunkett W, et al. Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood 2014;124(20):3059-64
118. Woyach JA, Johnson AJ. Targeted therapies in CLL: mechanisms of resistance and strategies for management. Blood 2015; 126(4):471-7
119. de Rooij MF, Kuil A, Kater AP, et al. Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. Blood 2015;125(14):2306-9
120. Dreger P, Schetelig J, Andersen N, et al. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood 2014;124(26):3841-9
121. Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood ASH Annual Meeting Abstracts 2009;114:abstr 1126
122. Jabbour EJ, Kantarjian H, Eliasson L, et al. Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol 2012;87(7): 687-91
123. Kohrt HE, Sagiv-Barfi I, Rafiq S, et al. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood 2014; 123(12):1957-60
124. Da Roit F, Engelberts PJ, Taylor RP, et al. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica 2015; 100(1):77-86
125. Zucca E, Bertoni F. Toward new treatments for mantle-cell lymphoma? N Engl J Med 2013;369(6):571-2
126. Zhang SQ, Smith SM, Zhang SY, Lynn Wang Y. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. Br J Haematol 2015;170(4):445-56
127. Badoux XC, Keating MJ, Wen S, et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 2011;118(13):3489-98
128. Chen CI, Bergsagel PL, Paul H, et al. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol 2011;29(9):1175-81
129. Zaja F De Luca S, et al. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica 2012;97(3): 416-22
130. Morrison VA, Jung SH, Johnson J, et al. Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). Leuk Lymphoma 2015; 56(4):958-64
131. Hitz F, Fischer N, Pabst T, et al. Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial. Ann Hematol 2013;92(8):1033-40